StemRNA™ Clinical iPSCs
    Quality Control & Characterization Data

    Human iPSCs can differentiate into a wide range of specialized cell types, enabling applications in regenerative medicine. REPROCELL’s StemRNA™ Clinical iPSC Seed Clones are generated using integration-free RNA reprogramming and undergo extensive quality control to ensure genetic integrity and suitability for downstream clinical manufacturing.

    StemRNA™ Clinical iPSC Clones
    Functional Differentiation into Cytotoxic iNK Cells

     

    Live-cell imaging of human iNK cells interacting with tumor K562 cells. Elongated human iNK (induced Natural Killer) cells exhibit cytotoxic activity when co-cultured with CFSE-labeled K562 cells (green, round), a human chronic myeloid leukemia cell line. These data demonstrate that iNK cells display mature functional capacity to recognize and eliminate target cells.
    Data were generated in collaboration with the Tokyo Metropolitan Institute of Medical Science, Japan.  

    Every StemRNA Clinical iPSC Seed Clone, along with its donor material and any subsequent GMP MCB batch undergoes comprehensive genetic integrity testing. Low-resolution G-band karyotyping confirms normal overall chromosome structure and the absence of numeric aberrations and structural aberrations. For higher resolution analysis, whole genome sequencing-based oncogenic screening evaluates genetic variants across more than 400 cancer-related genes. A detailed oncogenic report which analyses interprets high-impact genetic variants using publicly available clinical databases, is provided for each ready-to-use clinical seed clone. 


    Quality Control Data of Typical StemRNA™ Clinical iPSC Clones  

    Morphology, P6+3

    GMP iPSC - QC data - Morphology

    Karyology

    GMP iPSC - QC data - Karyology

    Flow cytometry analysis 

    GMP iPSC - flow cytometry analysis

    3-germ layers differentiation potential measured by RT qPCR

    GMP iPSC - QC data - Germ Layers

    Typical quality control assays of Clinical StemRNA iPSC Lines. Typical quality control assays for Clinical StemRNA™ iPSC lines. To confirm suitability as starting material for clinical programs, each clonal line undergoes comprehensive validation, including cell count, post-thaw viability, sterility and mycoplasma testing, colony morphology and growth assessment, karyotyping, and pluripotency marker expression by flow cytometry. Functional pluripotency is further evaluated through directed differentiation into the three germ layers. Only clones meeting all batch release specifications are advanced to scale-up for GMP Master Cell Bank manufacturing.  Data generated in-house.  


    Efficient Neural Differentiation of StemRNA™ iPSCs 

    Clinical Stem Cells - Neural Differentiation

    Typical targeted differentiation of StemRNA™ clinical iPSC clones into the neural lineage. Cells were sequentially differentiated and assessed by flow cytometry, showing expression of stage-specific markers for neural progenitor cells, iGRPs (induced glia-restricted progenitor cells), and astrocytes. Data generated in-house. 


    Typical iNK Cell Differentiation of
    StemRNA™ Clinical iPSC Clones 

    iPSC-derived NK cells Figure-1

    Expression of key NK cell surface markers in iNK cells derived from StemRNA™ clinical iPSC clones REPROCELL's clinical iPSCs were differentiated into iNK cells and characterized by flow cytometry. CD45⁺CD56⁺ NK cells expressed NKp44 (CD336), NKp46 (CD335), and NKG2D (CD314), demonstrating markers typical of mature, functional iNK cells.
    Data generated in collaboration with the Tokyo Metropolitan Institute of Medical Science, Japan. 

    Explore Relevant Pages:

    Contact our experts 

    At REPROCELL, our scientists understand that your custom iPSC project must be as unique as your research. If you have any questions about how our Clinical iPSC Generation Service can help you advance your project, please make an inquiry using the form below.

    On our blog